Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910401 · ClinicalTrials.gov registry record · Phase 2
Clinical Response to Rhinovirus Challenge
A Phase 2 study, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT02910401 is a Phase 2 study that has completed, run by University of Virginia. The registered enrollment target is 38 participants.
The verdict
NCT02910401, a Phase 2 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
Rhinovirus (RV) infections represent the most common cause of asthma exacerbations in children and adolescents. The investigators hypothesize that the immune responses generated in the nose of allergic rhinitics and asthmatics underlie subsequent systemic modulation of the immune system, and that - in susceptible individuals (i.e., those with pre-existing asthma) - this modified nasal milieu is responsible for the asthma exacerbation. Open label single center study in asthmatics as well as allergic rhinitis (AR) and healthy controls. All subjects will undergo good manufacturing practice (GMP) RV16 inoculation and responses will be compared between the 3 cohorts.
Interventions
- BIOLOGICAL Rhinovirus (GMP RV16 HRV-16)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-09 |
| Est. Completion | 2022-09-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02910401
The ClinicalTrials.gov registry entry for NCT02910401 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rhinovirus (GMP RV16 HRV-16) is the first listed.
NCT02910401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02910401 about?
NCT02910401 is a clinical study titled "Clinical Response to Rhinovirus Challenge". Rhinovirus (RV) infections represent the most common cause of asthma exacerbations in children and adolescents. The investigators hypothesize that the immune responses generated in the nose of allergic rhinitics and asthmatics underlie subsequent systemic modulation of the immune system, and that - ...
What is the current status of trial NCT02910401?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2016-09. Estimated completion is 2022-09-21.
What interventions are being tested in trial NCT02910401?
The interventions under investigation include: Rhinovirus (GMP RV16 HRV-16) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02910401?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.